CDx Diagnostics

CDx Diagnostics is a privately held company based in Suffern, New York. Employing 84 people, the company has generated $50 million in revenue. CDx Diagnostics aims to revolutionize cancer detection by providing clinicians with accessible and cost-effective tools to identify precancerous cellular changes. Their proprietary diagnostic platform utilizes a combination of computer imaging, artificial intelligence, molecular biology, and three-dimensional cytopathology, enabling earlier and more reliable detection of precancerous changes compared to traditional methods. CDx Diagnostics offers diagnostic tests that require minimal training and are highly cost-effective and widely reimbursed. These tests address a critical gap in current diagnostic standards, aiming to prevent thousands of unnecessary cancer deaths annually. Their technology has already detected thousands of precancerous cells, allowing for timely endoscopic treatment. The company is currently expanding the application of their diagnostic platform to detect cancers of the bile duct, stomach, and colon affected by Inflammatory Bowel Disease. In addition to their core diagnostic platform, CDx Diagnostics also offers WATS3D, a technology designed to improve the accuracy of esophageal biopsies. WATS3D allows endoscopists to easily obtain a wide area, full-thickness transepithelial specimen for computer-assisted 3D laboratory analysis, significantly increasing the detection rate of Barrett’s esophagus and esophageal dysplasia. The system’s high sensitivity and inter-observer agreement are attributed to the larger tissue area sampled and its proprietary 3-Dimensional computer imaging system, powered by an artificial intelligence algorithm initially developed for the U.S. Strategic Defense Initiative missile defense program. For more information about CDx Diagnostics and their solutions, please visit their website at cdxdiagnostics.com.